X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PFIZER ALEMBIC PHARMA/
PFIZER
 
P/E (TTM) x 29.0 31.2 92.8% View Chart
P/BV x 6.6 5.0 133.2% View Chart
Dividend Yield % 0.7 0.7 109.1%  

Financials

 ALEMBIC PHARMA   PFIZER
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PFIZER
Mar-16
ALEMBIC PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7922,724 29.1%   
Low Rs4431,611 27.5%   
Sales per share (Unadj.) Rs167.0440.9 37.9%  
Earnings per share (Unadj.) Rs38.248.7 78.4%  
Cash flow per share (Unadj.) Rs42.075.8 55.4%  
Dividends per share (Unadj.) Rs4.0015.00 26.7%  
Dividend yield (eoy) %0.60.7 93.6%  
Book value per share (Unadj.) Rs84.9462.9 18.3%  
Shares outstanding (eoy) m188.5245.75 412.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.9 75.2%   
Avg P/E ratio x16.244.5 36.3%  
P/CF ratio (eoy) x14.728.6 51.4%  
Price / Book Value ratio x7.34.7 155.3%  
Dividend payout %10.530.8 34.0%   
Avg Mkt Cap Rs m116,38399,163 117.4%   
No. of employees `000NA2.9 0.0%   
Total wages/salary Rs m4,2142,758 152.8%   
Avg. sales/employee Rs ThNM6,981.7-  
Avg. wages/employee Rs ThNM954.5-  
Avg. net profit/employee Rs ThNM771.1-  
INCOME DATA
Net Sales Rs m31,48720,170 156.1%  
Other income Rs m55857 6.4%   
Total revenues Rs m31,54221,028 150.0%   
Gross profit Rs m10,0604,310 233.4%  
Depreciation Rs m7221,239 58.3%   
Interest Rs m375 707.7%   
Profit before tax Rs m9,3563,923 238.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m2,1601,794 120.4%   
Profit after tax Rs m7,1942,228 322.9%  
Gross profit margin %31.921.4 149.5%  
Effective tax rate %23.145.7 50.5%   
Net profit margin %22.811.0 206.9%  
BALANCE SHEET DATA
Current assets Rs m15,06616,299 92.4%   
Current liabilities Rs m7,6747,594 101.1%   
Net working cap to sales %23.543.2 54.4%  
Current ratio x2.02.1 91.5%  
Inventory Days Days6765 102.6%  
Debtors Days Days4126 157.8%  
Net fixed assets Rs m8,2378,622 95.5%   
Share capital Rs m377458 82.4%   
"Free" reserves Rs m15,41620,722 74.4%   
Net worth Rs m16,00521,180 75.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m24,59429,137 84.4%  
Interest coverage x255.2755.5 33.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.7 184.9%   
Return on assets %29.47.7 383.7%  
Return on equity %44.910.5 427.3%  
Return on capital %58.719.0 308.9%  
Exports to sales %55.70.1 93,689.9%   
Imports to sales %10.417.5 59.6%   
Exports (fob) Rs m17,55112 146,256.7%   
Imports (cif) Rs m3,2833,526 93.1%   
Fx inflow Rs m17,81152 34,483.1%   
Fx outflow Rs m5,318140 3,799.1%   
Net fx Rs m12,493-88 -14,143.0%   
CASH FLOW
From Operations Rs m9,3043,436 270.8%  
From Investments Rs m-3,105-6,991 44.4%  
From Financial Activity Rs m-1,959-619 316.6%  
Net Cashflow Rs m4,240-4,174 -101.6%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 4.9 185.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.7 58.6%  
Shareholders   49,328 85,207 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS